T-SIGn Platform Pipeline
R&D Programs and Progress
PsiOxus is pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment.
We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Flexibility provided by T-SIGn for encoding multiple transgenes unlocks a multitude of therapeutic strategies with novel payload/payload combinations in one treatment modality.
Our lead clinical studies cover various mechanisms of action including direct T cell engagement, activation of immuno-inflammatory response and targeting tumor-associated stromal fibroblasts.
Click here for information on the NG-350A study (FORTITUDE)
Click here for information on the NG-641 study (STAR)
Click here for information on the NG-641 study (MOAT)